Carlsmed (CARL) Q2 2026 earnings review
Blistering Top-Line Growth and CMS Catalyst Clouded by Runaway OpEx
Carlsmed continues to execute flawlessly on its revenue and margin targets. Q2 2026 revenue surged 57% YoY to $18.9M, driven by a 60% expansion in trained surgeons and successful cross-selling of the aprevo cervical product (now 10% of revenue). Gross margin expanded 340 bps YoY to 76.8%, proving the company's digital manufacturing scale can absorb lower-ASP cervical products. Furthermore, the finalization of the CMS IPPS rule for FY2027 significantly de-risks future hospital adoption. However, the 'path to profitability' narrative took a hit: operating expenses spiked 66% YoY, outpacing revenue growth and causing the net loss to widen by 55% to $10.5M. The top line is accelerating, but the cash burn is a growing concern.
🐂 Bull Case
The FY2027 CMS IPPS rule was finalized to include three new MS-DRG codes with favorable reimbursement for inpatient aprevo lumbar procedures. This removes ambiguity and alters hospital economics permanently in Carlsmed's favor.
In just its second full quarter, aprevo cervical represents 10% of revenue (approx. $1.9M). It validates the company's ability to cross-sell to its existing surgeon base and attack the 370,000 annual cervical procedure market.
🐻 Bear Case
Despite 57% revenue growth and stellar gross margins, net loss widened from $6.8M to $10.5M YoY. G&A expenses skyrocketed 128% YoY, pushing out the timeline for achieving cash flow breakeven.
Adjusted EBITDA loss worsened to $8.6M (from $6.2M a year ago). While the company has $89.3M in liquidity, the accelerating burn rate contradicts management's prior claims of near-term operating leverage.
⚖️ Verdict: 🟢
Bullish. The widening net loss is frustrating, but 57% top-line growth, 76.8% gross margins, and a permanently de-risked reimbursement landscape (via CMS) form a phenomenal foundation for a medical device disruptor.
Key Themes
CMS IPPS Rule Finalized: The Ultimate Catalyst
In Q1, management cited the *proposed* CMS rule as a critical milestone. In Q2, this rule was finalized for FY2027, officially creating three new MS-DRG codes for inpatient aprevo lumbar procedures. This transforms the sales cycle from a hospital value-analysis committee fight into a highly favorable economic proposition, paving the way for accelerating adoption starting October 2026.
Manufacturing Scale Sustains Premium Gross Margins
Stable. There was concern in prior quarters that the lower Average Selling Price (ASP) of cervical implants would compress overall margins. Instead, gross margin came in at a robust 76.8%, up 340 basis points from Q2 2025. Carlsmed's AI-enabled, just-in-time digital production system continues to yield structural efficiencies that easily offset the cervical mix-down.
Surgeon Adoption Flywheel
Accelerating. The total trained surgeon user base grew by over 60% YoY, carrying over the momentum seen in late 2025 and Q1 2026. Management specifically noted strong engagement from early-career and post-fellowship surgeons, indicating that personalized implants are increasingly being viewed as the modern standard of care rather than a niche tool.
G&A Expenses Decoupling from Revenue
Reversing. In previous calls, management emphasized gaining operating leverage. However, General and Administrative (G&A) expenses absolutely exploded in Q2, rising 128% YoY to $7.6M (vs $3.3M in Q2 2025). This single line item entirely erased the $5.6M YoY gain in gross profit, driving the expanded net loss. Management needs to explain if this includes one-time items or if the baseline corporate overhead has permanently shifted.
Multi-Product Platform Validated
The aprevo cervical product, launched in December 2025, now accounts for approximately 10% of revenue in its second full quarter. This rapid uptake validates the thesis that Carlsmed is a multi-segment platform, not a single-trick lumbar company. It also de-risks the upcoming Q4 2026 launches of the bi-lateral posterior lumbar procedure and corra cervical plating system.
Other KPIs
Up 51% YoY from $7.9M in Q2 2025. While absolute dollars are rising rapidly to fund the commercial footprint, S&M is actually growing slightly slower than Revenue (57%). This indicates modest operating leverage in customer acquisition, even if G&A is currently out of control.
Down from $97.1M at the end of Q1 2026. This implies a quarterly cash burn of roughly $7.8M. At the current burn rate, Carlsmed has approximately 11 quarters of runway, meaning near-term dilution risk is low despite the widening net loss.
Guidance
Accelerating. The company raised its full-year revenue outlook from the prior $72M - $77M range. The $76M midpoint implies over 50% YoY growth compared to FY2025's $50.5M. This reflects high confidence in the back-half commercial pipeline and ongoing cervical product ramp.
Key Questions
G&A Expense Explosion
General and Administrative expenses jumped 128% YoY, far outpacing top-line growth. What specific investments or one-time items drove this, and when can investors expect G&A to scale proportionally with revenue?
CMS IPPS Final Rule Impact Timeline
With the FY2027 CMS rule now finalized and taking effect October 1, 2026, what is your assumed lag time before this translates into faster hospital committee approvals and a tangible acceleration in procedure volume?
Cervical ASP Mix Dynamics
Cervical now represents 10% of revenue. Given the lower ASP of cervical procedures, what was the blended Average Revenue Per Procedure in Q2, and how much further can manufacturing efficiencies offset this mix-down effect on gross margins?
Pipeline Launch Readiness
Are the planned Q4 2026 commercial launches for the bi-lateral posterior lumbar procedure and the corra cervical plating system fully on track, and are they factored into the raised $74-$78M revenue guidance?